JP7344973B2 - 標的実体を検出するためのシステム、組成物、及び方法 - Google Patents

標的実体を検出するためのシステム、組成物、及び方法 Download PDF

Info

Publication number
JP7344973B2
JP7344973B2 JP2021549902A JP2021549902A JP7344973B2 JP 7344973 B2 JP7344973 B2 JP 7344973B2 JP 2021549902 A JP2021549902 A JP 2021549902A JP 2021549902 A JP2021549902 A JP 2021549902A JP 7344973 B2 JP7344973 B2 JP 7344973B2
Authority
JP
Japan
Prior art keywords
target
cancer
detection
entity
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021549902A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521781A5 (https=
JP2022521781A (ja
JPWO2020180741A5 (https=
Inventor
ジョゼフ チャールズ セドラック，
ローラ テレサ ボートリン，
ダニエル パーカー セイラム，
Original Assignee
マーシー バイオアナリティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マーシー バイオアナリティクス， インコーポレイテッド filed Critical マーシー バイオアナリティクス， インコーポレイテッド
Publication of JP2022521781A publication Critical patent/JP2022521781A/ja
Publication of JP2022521781A5 publication Critical patent/JP2022521781A5/ja
Publication of JPWO2020180741A5 publication Critical patent/JPWO2020180741A5/ja
Application granted granted Critical
Publication of JP7344973B2 publication Critical patent/JP7344973B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6862—Ligase chain reaction [LCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/50—Other enzymatic activities
    • C12Q2521/501—Ligase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2545/00—Reactions characterised by their quantitative nature
    • C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
    • C12Q2545/101—Reactions characterised by their quantitative nature the purpose being quantitative analysis with an internal standard/control
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2021549902A 2019-03-01 2020-02-28 標的実体を検出するためのシステム、組成物、及び方法 Active JP7344973B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962812878P 2019-03-01 2019-03-01
US62/812,878 2019-03-01
US202062962722P 2020-01-17 2020-01-17
US62/962,722 2020-01-17
PCT/US2020/020529 WO2020180741A1 (en) 2019-03-01 2020-02-28 Systems, compositions, and methods for target entity detection

Publications (4)

Publication Number Publication Date
JP2022521781A JP2022521781A (ja) 2022-04-12
JP2022521781A5 JP2022521781A5 (https=) 2023-03-09
JPWO2020180741A5 JPWO2020180741A5 (https=) 2023-03-09
JP7344973B2 true JP7344973B2 (ja) 2023-09-14

Family

ID=72338354

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549902A Active JP7344973B2 (ja) 2019-03-01 2020-02-28 標的実体を検出するためのシステム、組成物、及び方法

Country Status (9)

Country Link
US (3) US11085089B2 (https=)
EP (2) EP3931351B1 (https=)
JP (1) JP7344973B2 (https=)
KR (1) KR102599718B1 (https=)
CN (1) CN113748217B (https=)
AU (2) AU2020233286B2 (https=)
CA (1) CA3129868A1 (https=)
SG (1) SG11202109423TA (https=)
WO (1) WO2020180741A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020233286B2 (en) 2019-03-01 2022-10-20 Mercy Bioanalytics, Inc. Systems, compositions, and methods for target entity detection
DE102020003794A1 (de) * 2020-06-25 2021-12-30 Forschungszentrum Jülich GmbH Verfahren, Verwendung des Verfahrens sowle Kit zum Nachweis von Bioindikatoren in einer Probe
EP4301782A1 (en) 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
EP4373975A4 (en) * 2021-07-21 2025-04-23 Mercy Bioanalytics, Inc. COMPOSITIONS AND METHODS FOR THE DETECTION OF PANCREATIC CANCER
US20250297317A1 (en) * 2021-07-21 2025-09-25 Mercy Bioanalytics, Inc. Compositions and methods for detection of liver cancer
WO2023004083A2 (en) * 2021-07-21 2023-01-26 Mercy Bioanalytics, Inc. Compositions and methods for detection of bile duct cancer
US20250043357A1 (en) * 2021-07-21 2025-02-06 Mercy Bioanalytics, Inc. Compositions and methods for detection of esophageal cancer
EP4373860A4 (en) * 2021-07-21 2025-05-21 Mercy Bioanalytics, Inc. COMPOSITIONS AND METHODS FOR THE DETECTION OF PROSTATE CANCER
EP4374172A4 (en) * 2021-07-21 2025-05-14 Mercy Bioanalytics, Inc. COMPOSITIONS AND METHODS FOR DETECTING BREAST CANCER
EP4374173A4 (en) * 2021-07-21 2026-02-25 Mercy Bioanalytics Inc CANCER COMPOSITIONS AND DETECTION METHODS
WO2023004077A2 (en) * 2021-07-21 2023-01-26 Mercy Bioanalytics, Inc. Compositions and methods for detection of colorectal cancer
JP2024531915A (ja) 2021-08-05 2024-09-03 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｍｕｃ抗体およびその使用
CA3230934A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
AU2022339819A1 (en) 2021-09-03 2024-04-11 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
WO2023091618A1 (en) * 2021-11-17 2023-05-25 Mercy Bioanalytics, Inc. Compositions and methods for detection of ovarian cancer
EP4623094A1 (en) * 2022-11-23 2025-10-01 Range Biotechnologies, Inc. Compositions and methods for detection of protein analytes
WO2025252658A1 (en) 2024-06-03 2025-12-11 Olink Proteomics Ab New product and method

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118987A1 (en) 1992-11-06 2003-06-26 Charles R. Cantor Positional sequencing by hybridization
US20070275375A1 (en) 2003-06-17 2007-11-29 Keygene N.V. Means and Method for the Detection of Target Nucleotide Sequences Using Ligation Assays With Improved Oligonucleotide Probe Pairs
WO2015175856A1 (en) 2014-05-15 2015-11-19 Meso Scale Technologies, Llc. Improved assay methods
WO2016093838A1 (en) 2014-12-11 2016-06-16 New England Biolabs, Inc. Enrichment of target sequences

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2118759C (en) 1993-04-21 2004-06-22 William Jeffrey Allard Diagnosis and monitoring of lung cancer patients by measurement of nca 50/90 in blood
US20020025519A1 (en) * 1999-06-17 2002-02-28 David J. Wright Methods and oligonucleotides for detecting nucleic acid sequence variations
US7306904B2 (en) 2000-02-18 2007-12-11 Olink Ab Methods and kits for proximity probing
US8013134B2 (en) 2001-11-23 2011-09-06 Olink Ab Kit for proximity probing with multivalent proximity probes
AU2004232976B2 (en) 2003-04-18 2011-02-10 Becton, Dickinson And Company Immuno-amplification
US7914987B2 (en) 2004-06-14 2011-03-29 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in analyte detection using proximity probes
GB0605584D0 (en) 2006-03-20 2006-04-26 Olink Ab Method for analyte detection using proximity probes
US8758991B2 (en) 2006-04-26 2014-06-24 University Of Louisville Research Foundation, Inc. Isolation of membrane vesicles from biological fluids and methods of using same
US7892760B2 (en) 2007-11-19 2011-02-22 Celera Corporation Lung cancer markers, and uses thereof
US8481698B2 (en) 2009-03-19 2013-07-09 The President And Fellows Of Harvard College Parallel proximity ligation event analysis
GB201004292D0 (en) 2010-03-15 2010-04-28 Olink Ab Assay for localised detection of analytes
EP2627781B1 (en) 2010-10-15 2017-02-22 Olink Bioscience AB Dynamic range methods
JP6219721B2 (ja) 2010-11-10 2017-10-25 エキソソーム ダイアグノスティックス インコーポレイテッド 核酸含有粒子の単離および該粒子からの核酸の抽出のための方法
GB201101621D0 (en) 2011-01-31 2011-03-16 Olink Ab Method and product
CA2835641C (en) 2011-05-11 2019-05-28 Exosome Diagnostics, Inc. Nucleic acid extraction from heterogeneous biological materials
US9745616B2 (en) * 2011-05-17 2017-08-29 Dxterity Diagnostics Incorporated Methods and compositions for detecting target nucleic acids
GB201108678D0 (en) 2011-05-24 2011-07-06 Olink Ab Multiplexed proximity ligation assay
EP2776587A4 (en) 2011-11-10 2015-07-15 Exosome Diagnostics Inc LIQUOR ASSAY
US9029086B2 (en) 2012-01-26 2015-05-12 Masood Kamali Moghaddam Detection of single and multimodal analytes
WO2014015149A2 (en) 2012-07-18 2014-01-23 Exosome Diagnostics, Inc. Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
CA2887058C (en) 2012-10-03 2022-02-22 Exosome Diagnostics, Inc. Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
WO2014076209A1 (en) 2012-11-14 2014-05-22 Olink Ab Localised rca-based amplification method
WO2014076214A1 (en) 2012-11-14 2014-05-22 Olink Ab Rca reporter probes and their use in detecting nucleic acid molecules
US9086412B2 (en) 2012-12-31 2015-07-21 University Of Louisville Research Foundation, Inc. Extracellular vesicle-associated protein markers of cancer
EP2941629B1 (en) 2013-01-03 2018-10-10 Exosome Diagnostics Inc. Methods for isolating microvesicles
AU2014305994B2 (en) 2013-08-06 2019-02-21 Exosome Diagnostics, Inc. Urine biomarker cohorts, gene expression signatures, and methods of use thereof
AU2014312211A1 (en) * 2013-08-28 2016-03-10 Caris Science, Inc. Oligonucleotide probes and uses thereof
CN105745334B (zh) 2013-09-30 2019-12-10 吴迪 通过使用邻近条形编码分析分子复合物的概况的方法
GB201401885D0 (en) 2014-02-04 2014-03-19 Olink Ab Proximity assay with detection based on hybridisation chain reaction (HCR)
EP3366784B1 (en) 2014-02-28 2019-11-13 Exosome Sciences Inc. Brain specific exosome based diagnostics and extracorporeal therapies
AU2015269103B2 (en) * 2014-06-06 2021-12-23 Cornell University Method for identification and enumeration of nucleic acid sequence, expression, copy, or DNA methylation changes, using combined nuclease, ligase, polymerase, and sequencing reactions
WO2015193427A1 (en) 2014-06-19 2015-12-23 Olink Ab Determination and analysis of biomarkers in clinical samples
US11175286B2 (en) * 2015-01-09 2021-11-16 Spot Biosystems Ltd. Immunolipoplex nanoparticle biochip containing molecular probes for capture and characterization of extracellular vesicles
WO2016145128A1 (en) * 2015-03-09 2016-09-15 Caris Science, Inc. Oligonucleotide probes and uses thereof
CN114217058A (zh) * 2015-09-22 2022-03-22 波士顿大学董事会 纳米囊泡的多重表型分析
GB201518655D0 (en) 2015-10-21 2015-12-02 Olink Ab Method for generating proximity probes
US10526665B2 (en) * 2016-03-04 2020-01-07 University Of Notre Dame Du Lac Exosomal biomarkers diagnostic of tuberculosis
PT3464628T (pt) * 2016-06-06 2024-06-03 Redvault Biosciences Lp Construções repórter de alvo e suas utilizações
JP7280823B2 (ja) * 2016-11-30 2023-05-24 エクソサム ダイアグノスティクス，インコーポレイティド 非小細胞肺癌患者由来のエクソソームｒｎａ及び無細胞ｄｎａを使用して血漿中の変異を検出するための方法と組成物
WO2018119455A1 (en) 2016-12-23 2018-06-28 Exosome Diagnostics, Inc. Biofluid analysis and quantitation systems and methods
US11899024B2 (en) 2017-07-12 2024-02-13 Exosome Diagnostics, Inc. Treatment and diagnosis of parkinson's disease using isolated and enriched populations of biofluid-derived extracellular vesicles
WO2019018537A1 (en) 2017-07-18 2019-01-24 Exosome Diagnostics, Inc. NUCLEIC ACID SEQUENCING ASSOCIATED WITH EXOSOMAL ISOLATION IN PATIENTS WITH MULTIPLE GLIOBLASTOMA
WO2019022542A2 (ko) 2017-07-26 2019-01-31 ㈜로제타엑소좀 양이온을 이용한 세포밖 소포체의 분리 방법
EP3660142A4 (en) 2017-07-26 2021-05-05 Rosetta Exosome METHOD OF ISOLATION OF EXTRACELLULAR VESICLES USING CATIONS
WO2019066501A1 (ko) 2017-09-27 2019-04-04 ㈜로제타엑소좀 크기 배제 크로마토그래피를 이용한 세포밖 소포체의 분석 방법 및 이의 용도
WO2019103548A2 (ko) 2017-11-24 2019-05-31 ㈜로제타엑소좀 반건식 크기 배제 크로마토그래피를 이용한 세포밖 소포체의 분리 방법
WO2019113499A1 (en) * 2017-12-07 2019-06-13 The Broad Institute, Inc. High-throughput methods for identifying gene interactions and networks
US12480940B2 (en) * 2018-05-17 2025-11-25 Meso Scale Technologies, Llc. Methods for isolating surface marker displaying agents
WO2019236853A1 (en) 2018-06-06 2019-12-12 Exosome Diagnostics, Inc. Methods for developing urine biomarkers and for detecting bladder cancer
WO2019238944A1 (en) 2018-06-15 2019-12-19 Olink Proteomics Ab Biomarker panel for ovarian cancer
WO2020086751A1 (en) * 2018-10-23 2020-04-30 Meso Scale Technologies, Llc. Methods for isolating surface marker displaying agents
WO2020106853A1 (en) 2018-11-20 2020-05-28 Exosome Diagnostics, Inc. Compositions and methods for internal controls of microvesicle isolations
AU2020233286B2 (en) 2019-03-01 2022-10-20 Mercy Bioanalytics, Inc. Systems, compositions, and methods for target entity detection
US20230243834A1 (en) * 2020-01-17 2023-08-03 Mercy Bioanalytics, Inc. Compositions and methods for detection of ovarian cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118987A1 (en) 1992-11-06 2003-06-26 Charles R. Cantor Positional sequencing by hybridization
US20070275375A1 (en) 2003-06-17 2007-11-29 Keygene N.V. Means and Method for the Detection of Target Nucleotide Sequences Using Ligation Assays With Improved Oligonucleotide Probe Pairs
WO2015175856A1 (en) 2014-05-15 2015-11-19 Meso Scale Technologies, Llc. Improved assay methods
WO2016093838A1 (en) 2014-12-11 2016-06-16 New England Biolabs, Inc. Enrichment of target sequences

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M. Lundberg, et al.，Molecular & Cellular Proteomics，2011年，Vol.10, No.4，p.1-10
M. Lundberg, et al.，Nucleic Acids Research，2011年，Vol.39, No.15, e102，p.1-8

Also Published As

Publication number Publication date
EP3931351A1 (en) 2022-01-05
EP3998349A3 (en) 2022-08-24
AU2022241629B2 (en) 2025-05-29
AU2020233286B2 (en) 2022-10-20
JP2022521781A (ja) 2022-04-12
EP3998349A2 (en) 2022-05-18
EP3931351B1 (en) 2024-09-11
US11085089B2 (en) 2021-08-10
EP3931351A4 (en) 2022-05-11
KR102599718B1 (ko) 2023-11-09
AU2022241629A1 (en) 2022-10-27
US20200299780A1 (en) 2020-09-24
AU2022241629C1 (en) 2026-04-09
AU2020233286A1 (en) 2021-10-14
US20210214806A1 (en) 2021-07-15
CN113748217B (zh) 2023-08-25
US20220155304A1 (en) 2022-05-19
CN113748217A (zh) 2021-12-03
SG11202109423TA (en) 2021-09-29
WO2020180741A1 (en) 2020-09-10
KR20210141952A (ko) 2021-11-23
CA3129868A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
JP7344973B2 (ja) 標的実体を検出するためのシステム、組成物、及び方法
US20230243834A1 (en) Compositions and methods for detection of ovarian cancer
KR20230044429A (ko) 폐암의 검출을 위한 조성물 및 방법
WO2023004083A2 (en) Compositions and methods for detection of bile duct cancer
WO2023004079A2 (en) Compositions and methods for detection of liver cancer
US20240377401A1 (en) Compositions and methods for detection of prostate cancer
EP4374172A2 (en) Compositions and methods for detection of breast cancer
US20240369560A1 (en) Compositions and methods for detection of pancreatic cancer
US20240344139A1 (en) Compositions and methods for detection of colorectal cancer
HK40076883A (en) Compositions and methods for target protein detection on exosomes using proximal ligation
HK40066670B (en) Method for target entity detection using ligase
HK40066670A (en) Method for target entity detection using ligase
US20250327129A1 (en) Compositions and methods for detection of ovarian cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230228

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230713

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230901

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230904

R150 Certificate of patent or registration of utility model

Ref document number: 7344973

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150